Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Invasive squamous-cell carcinoma of the anal canal in HIV-infected patients, and outcomes in patients undergoing highly active antiretroviral therapy

Researchers in Germany and Texas have conducted a study investigating outcomes in patients with HIV who have also been diagnosed with invasive squamous-cell carcinoma of the anal canal.

News image

fiogf49gjkf04

Writing in the August issue of the journal Diseases of the Colon & Rectum, the researchers note that in the past, prior to the development of highly active retroviral therapy for the treatment of HIV infection, HIV patients diagnosed with invasive squamous-cell carcinoma of the anal canal carried a very poor diagnosis.

This study was designed to determine the outcome in a similar group of patients in the era of highly active antiretroviral therapy.

The scientists identified HIV-positive patients treated for invasive squamous-cell carcinoma of the anal canal at the University of Texas Medical Center affiliated hospitals from 1980 to 2001. Patients were identified from operative data and cancer registries.

The records were reviewed and data was collected regarding age, CD4 count, highly active antiretroviral therapy, cancer treatment, complications, and survival.

Pre-highly active antiretroviral therapy group – all 6 patients died with active squamous-cell carcinoma
Highly active antiretroviral therapy group – 2 of 6 patients died with active squamous-cell carcinoma
Diseases of the Colon & Rectum

The patients were then divided into two groups based on the presence or absence of highly active antiretroviral therapy and compared using a Kaplan-Meier approach.

In total, 14 patients with HIV and invasive squamous-cell carcinoma of the anal canal were identified, of whom 6 were in the pre-highly active antiretroviral therapy group and 8 in the highly active antiretroviral therapy group. All were considered for treatment with chemotherapy and radiation.

In the pre-highly active antiretroviral therapy group, one patient refused therapy and 3 were unable to complete the squamous-cell carcinoma therapy as planned because of complications.

This compared to 4 of the 8 highly active antiretroviral therapy patients who were unable to complete the squamous-cell carcinoma therapy as planned.

The pre-highly active antiretroviral therapy patients had a mean age of 40 years and a mean CD4 count of 190 at the time of diagnosis.

The highly active antiretroviral therapy patients had a mean age of 44 years and a mean CD4 count of 255 at the time of diagnosis.

The 24-month survival was 17% in the pre-highly active antiretroviral therapy group and 67% in the highly active antiretroviral therapy group.

All 6 patients in the pre-highly active antiretroviral therapy group died with active squamous-cell carcinoma vs. 2 in the highly active antiretroviral therapy group.

In total, 4 of the remaining 6 patients had no evidence of active squamous-cell carcinoma at the last follow-up visit.

Commenting on their findings, the researchers said, "A review of patients with HIV and invasive squamous-cell carcinoma of the anal canal suggests a trend toward a higher CD4 count at the time of diagnosis and improved survival in patients receiving highly active antiretroviral therapy."

They added, "In this new era, HIV-positive patients should be on highly active antiretroviral therapy. If not, highly active antiretroviral therapy should be initiated, and standard multimodality therapies for invasive squamous-cell carcinoma of the anal canal are recommended."

Dis Colon Rectum 2004; 47 (8): 1305 - 1309
15 September 2004

Go to top of page Email this page Email this page to a colleague

 24 May 2018 
Precision medicine for tumors
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 23 May 2018 
High body mass index is and ulcerative colitis
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Fecal incontinence and quality of life in IBD
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us